Modulation of the brain to affect psychiatric disorders

• US 6,708,064 B2
• Filed: 12/24/2001
• Issued: 03/16/2004
• Est. Priority Date: 02/24/2000
• Status: Expired due to Term

• Current Assignee: Ali R. Rezai
• Original Assignee: Ali R. Rezai
• Inventors: Rezai, Ali R.
• Primary Examiner(s): Layno, Carl
• Application Number:
  US10/036,340
• Publication Number:
  US 20020151939A1
• Time in Patent Office: 813 Days
• Field of Search: 607/45, 607/2, 607/3
• US Class Current: 607/45
• CPC Class Codes: A61N 1/36082 Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease

Abstract

A method for treating neurological conditions by proper placement of a probe and sensing, stimulating or both areas of the brain especially the intralaminar nuclei (ILN”). Moreover, stimulation is controlled and offered when certain conditions within the area of interest are detected. Stimulation and sensing include electrical, chemical or combinations thereof.

Claims

1. A method of treating a disorder associated with a specific area in a brain comprising:

implanting a device in contact with an intralaminar nuclei of the brain;

sensing activity in the specific area of the brain, wherein the specific area of the brain is different than the intralaminar nuclei, and wherein the specific area of the brain is different than the intralaminar nuclei and the sensing activity occurs at a location distal from the device location; and

operating the device to modulate the intralaminar nuclei in response to said activity to thereby affect the disorder associated with the specific area of the brain.

2. The method of claim 1, wherein the device is an electrode assembly.

3. The method of claim 1, wherein the activity being sensed is electrical activity.

4. The method of claim 1, wherein the device is sustained-release matrix.

5. The method of claim 1, wherein said specific area is selected from the group consisting of the pre-frontal cortex, orbitofrontal cortex, anterior limb of the internal capsule, Nucleus Accumbens, ventral striatum, the ventral Pallidum anterior nucleus of the thalamus, dorsomedial nucleus of the thalamus, intralaminar thalamic nuclei, the cingulate cortex, Amygdala, Hippocampus, Mamillary bodies, the lateral hypothalamus, the Locus Ceruleus, the Dorsal Raphe Nucleus, ventral tegmentum, the Substantia Nigra Pars Compacta and reticulata.

6. The method of claim 1, wherein said disorder is selected from the group consisting of obsessive compulsive disorder, generalized anxiety disorder, post traumatic stress disorder, panic attacks, social phobia, major depression, bipolar disorder, schizophrenia, and substance abuse disorders/additions.

7. The method of claim 1, wherein said step of sensing occurs epidurally, subdurally, or on the scalp.

8. The method of claim 1, wherein said step of sensing occurs at the local milieu of the electrode.

9. A method of affecting a psychiatric activity in a specific area of the brain comprising:

placing an electrode in contact with an intralaminar nuclei of the brain; and

operating the device to provide stimulation to the intralaminar nuclei to thereby affect the psychiatric activity in the specific area of the brain, the specific area of the brain being different than the intralaminar nuclei.

10. The method of claim 9, wherein the stimulation is electrical.

11. The method of claim 10, wherein the device is an electrode assembly.

12. The method of claim 9, wherein the stimulation is chemical.

13. The method of claim 12, wherein the device is a sustained-release matrix.

14. The method of claim 9, wherein said specific area is selected from the group consisting of the pre-frontal cortex, orbitofrontal cortex, anterior limb of the internal capsule. Nucleus Accumbens, ventral striatum, the ventral Pallidum anterior nucleus of the thalamus, dorsomedial nucleus of the thalamus, intralaminar thalamic nuclei, the cingulate cortex, Amygdala, Hippocampus, Mamillary bodies, the lateral hypothalamus, the Locus Ceruleus, the Dorsal Raphe Nucleus, ventral tegmentum, the Substantia Nigra Pars Compacta and reticulate.

15. A method of affecting psychiatric activity in a patient comprising:

identifying a portion of the patient'"'"'s ILN intralaminar nuclei which is in communication with a predetermined region of the patient'"'"'s brain, said predetermined region of said patient'"'"'s brain being associated with the psychiatric activity;

and modulating the portion of the patient'"'"'s ILN to effectuate the psychiatric activity.

16. The method of claim 15, wherein the identification of a portion of the patient'"'"'s intralaminar nuclei is based upon a composite of other patient'"'"'s intralaminar nuclei activity.

17. The method of claim 15, wherein the identifying step is independent of an exhibition of a pathologic condition in the predetermined region of said patient'"'"'s brain.

18. The method of claim 15, wherein the psychiatric activity is selected from the group consisting of happiness, fear, anger, anxiety, euphoria, and sadness.

19. The method of claim 15, wherein the modulation of the portion of the patient'"'"'s ILN is accomplished using chemical stimulation.

23. The method of claim 17, wherein said step of sensing occurs epidurally, subdurally, or on the scalp.

20. A method of treating a disorder associated with specific area in a brain comprising:

implanting a device wherein the device includes a sustained release matrix in contact with an intralaminar nuclei of the brain;

sensing activity in the specific area of the brain, wherein the sensing activity occurs at a location distal from the device location; and

operating the device to modulate the intralaminar nuclei in response to said activity to thereby affect the disorder associated with the specific area of the brain.

21. The method of claim 20, wherein modulation occurs via release of a chemical from the sustained release matrix.

22. The method of claim 20, wherein the specific area of the brain in which the device is implanted is different than the intralaminar nuclei.